Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ChemoCentryx has commenced the Phase II clinical trial for CCX168, an orally-administered small molecule used to treat anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease that can cause renal and pulmonary failure.
Subscribe to our email newsletter
CCX168 specifically targets the C5a receptor, a pro-inflammatory mediator that is involved in AAV as well as other autoimmune diseases.
The randomized, double-blind, placebo-controlled trial will assess the safety and tolerability of CCX168 in patients with ANCA-associated renal vasculitis besides determining the potential to reduce the use of corticosteroids in these patients.
ChemoCentryx president and CEO Thomas J Schall said the company has demonstrated the capabilities of drug discovery platform in blocking specific chemokines and chemoattractant cytokines in the treatment of autoimmune and inflammatory diseases.